Ann: 2018 AGM Presentation, page-23

This is now correct, in 1 year development has been poor and we are today on the same level as 2 y ago. During the previous year share price came from this 1.60 level up almost 100 %. But even 3.18 is very poor value if you compare what it was just before the results of Imagine study. So I do agree totally that market has lost much of its interest in this stock if you look at the share price. On the volume side evidence is not so clear ( volumes are low ) and volatility is very high.
The value of this stock is only in it's goal: to help neurodegeneration patient with the drugs it has developed. If it cannot help them there is no hope with Prana but if it can and does it better than other drug companies there is still a great future IMO. But this is only my opinion and it is not an advice to anybody to invest in Prana.